PTC Therapeutics Aktie
42,00
EUR
-0,40
EUR
-0,94
%
48,74
USD
-0,16
USD
-0,33
%
Werbung
PTC Therapeutics Aktie Analyse
01.10.18 | PTC Therapeutics Overweight | Cantor Fitzgerald | |
01.03.16 | PTC Therapeutics overweight | Barclays Capital | |
24.02.16 | PTC Therapeutics Outperform | Wedbush Morgan Securities Inc. | |
16.10.15 | PTC Therapeutics Outperform | Oppenheimer & Co. Inc. | |
16.10.15 | PTC Therapeutics Outperform | RBC Capital Markets | |
31.07.15 | PTC Therapeutics Outperform | RBC Capital Markets | |
23.04.15 | PTC Therapeutics Outperform | Oppenheimer & Co. Inc. | |
09.04.15 | PTC Therapeutics Buy | Deutsche Bank AG | |
Werbung
|
|||
04.03.15 | PTC Therapeutics overweight | Barclays Capital | |
02.03.15 | PTC Therapeutics Buy | ROTH Capital Partners, LLC | |
23.01.15 | PTC Therapeutics Outperform | RBC Capital Markets | |
29.09.14 | PTC Therapeutics Buy | ROTH Capital Partners, LLC |
Werbung
Werbung